Research

lf0 Research Notes

Get future lf0 equity research notes by email.

Weekly stock analysis, SEC filing-change summaries, and quant strategy notes from lf0.

Subscribe to lf0 Research Notes

SEC What Changed
SWBI
Smith & Wesson Brands (SWBI) 2026 10-K Analysis: MD&A Changes
Jun 17, 2026
Smith & Wesson Brands (SWBI) 2026 10-K analysis comparing the 17 June 2026 filing with its prior-year 10-K, highlighting the MD&A section’s biggest changes.
Read note
SEC What Changed
SEC
SEC What Changed: 10-K Filing Snapshot for 16 June 2026
Jun 16, 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 16 June 2026.
Read note
Equity Research
TER
Teradyne Stock Analysis: Valuation, AI Demand, Margins & Growth
Jun 15, 2026
Teradyne (TER) is rated HOLD as strong AI-driven growth and operating leverage are already offset by a steep valuation. Q1 2026 revenue rose 87% year over year, but customer concentration and rich multiples limit the upside.
Read note
SEC What Changed
AIOT, CGC, CRDO, GWAV, VTGN
Vistagen Therapeutics (VTGN) 10-K Changes Lead 15 June 2026 Filing Roundup
Jun 15, 2026
Vistagen Therapeutics (VTGN) led the biggest 10-K filing change among 7 companies that filed annual reports on 15 June 2026, each compared against its…
Read note
Equity Research
SOUN
SoundHound AI Stock Analysis: Valuation, Cash Burn, Margins & Customer Risk
Jun 14, 2026
SoundHound AI (SOUN) is rated SELL as rapid revenue growth is offset by weak profitability and ongoing cash burn. The stock trades at 15.1x EV/revenue while TTM operating cash flow was -$105.3M and levered free cash flow was -$16.7M, leaving little room for error.
Read note
Equity Research
SYM
Symbotic Stock Analysis: Valuation, Margins, Cash Flow & Growth
Jun 14, 2026
Symbotic (SYM) is rated Hold as revenue growth stays strong but profitability remains early. TTM operating margin was flat and customer concentration is high, even as debt is low and deployment-driven growth continues.
Read note
Equity Research
BSX
Boston Scientific Stock Analysis: Valuation, Reimbursement Risk, Cash Flow & Growth
Jun 14, 2026
Boston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow. The key question is whether management can sustain execution while navigating reimbursement pressure and acquisition-led capital deployment.
Read note
Equity Research
TEAM
Atlassian Stock Analysis: Valuation, Cloud Migration, Margins & Cash Flow
Jun 14, 2026
Atlassian (TEAM) earns a HOLD rating as its subscription software base and strong cash generation offset weak profitability. The key question is whether cloud migration and operating leverage can turn 3.6x EV/revenue into durable earnings power.
Read note
SEC What Changed
SEC
SEC What Changed: 10-K Filing Snapshot for 12 June 2026
Jun 12, 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 12 June 2026.
Read note
SEC What Changed
SEC
SEC What Changed: 10-K Filing Snapshot for 11 June 2026
Jun 11, 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 11 June 2026.
Read note

Get future lf0 research notes by email.

Equity research, SEC filing-change summaries, and quant research — delivered when published. Free, no noise.

Subscribe to lf0 Research Notes

No spam. Unsubscribe anytime.